Cerenome, Inc.
Income Statement
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $411.0K | $1.0M | $1.4M | $1.4M | $1.4M | $1.1M | $1.4M | $1.5M |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $4.3M | $2.9M | $2.9M | $2.4M | $1.2M | $1.8M | $2.2M | $2.9M |
| SG&A Expense | $5.2M | $5.3M | $4.2M | $3.4M | $1.7M | $2.8M | $3.1M | $2.4M |
| Operating Income | $-9.1M | $-7.1M | $-5.7M | $-4.5M | $-1.5M | $-3.5M | $-3.9M | $-3.8M |
| Operating Margin | -2,203.6% | -692.5% | -420.0% | -320.8% | -110.6% | -333.9% | -276.2% | -260.9% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | — | — | — | — | — | — | — |
| Income Tax Expense | — | — | — | — | — | — | — | — |
| Net Income | $-9.0M | $-6.9M | $-5.7M | $-4.4M | $5.2M | $-17.4M | $-3.9M | $-2.9M |
| Net Margin | -2,191.2% | -675.7% | -417.9% | -316.6% | 370.6% | -1,643.2% | -276.4% | -197.4% |
| EPS (Basic) | $-1.31 | $-1.05 | $28.99 | $0.00 | $0.06 | $-2.99 | $-0.04 | $-0.02 |
| EPS (Diluted) | $-1.31 | $-1.05 | $29.77 | $0.00 | $-0.02 | $-2.99 | $-0.05 | $-0.02 |
| Shares Outstanding (Basic) | 6.9M | 6.6M | 77.8M | 1.07B | 19.4M | 5.8M | 66.4M | 157.1M |
| Shares Outstanding (Diluted) | 6.9M | 6.6M | 77.8M | 1.07B | 83.7M | 5.8M | 77.0M | 157.1M |
| Dividends Per Share | — | — | — | — | — | — | — | — |